drugset / Trial / NCT01004224
A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The study will determine the maximum tolerated dose and thus the recommended phase II dose and schedule of the compound and characterize the safety.
Timeline
- Start
- 2009-12-11
- Primary completion
- 2018-10-08
- Completion
- 2018-10-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Infigratinib | Small molecule | — | Oral |